- Home
- AXIL vs INKT Comparison
AXIL vs INKT Comparison
Compare AXIL & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- INKT
- Stock Information
- Founded
- AXIL 2015
- INKT 2017
- Country
- AXIL United States
- INKT United States
- Employees
- AXIL N/A
- INKT N/A
- Industry
- AXIL Package Goods/Cosmetics
- INKT Medicinal Chemicals and Botanical Products
- Sector
- AXIL Consumer Discretionary
- INKT Health Care
- Exchange
- AXIL Nasdaq
- INKT Nasdaq
- Market Cap
- AXIL 52.6M
- INKT 75.7M
- IPO Year
- AXIL N/A
- INKT 2021
- Fundamental
- Price
- AXIL $8.19
- INKT $16.83
- Analyst Decision
- AXIL
- INKT Hold
- Analyst Count
- AXIL 0
- INKT 3
- Target Price
- AXIL N/A
- INKT $37.50
- AVG Volume (30 Days)
- AXIL 18.5K
- INKT 2.9M
- Earning Date
- AXIL 08-14-2025
- INKT 08-12-2025
- Dividend Yield
- AXIL N/A
- INKT N/A
- EPS Growth
- AXIL 93.65
- INKT N/A
- EPS
- AXIL 0.29
- INKT N/A
- Revenue
- AXIL $27,007,463.00
- INKT N/A
- Revenue This Year
- AXIL N/A
- INKT N/A
- Revenue Next Year
- AXIL N/A
- INKT N/A
- P/E Ratio
- AXIL $29.42
- INKT N/A
- Revenue Growth
- AXIL N/A
- INKT N/A
- 52 Week Low
- AXIL $3.54
- INKT $4.56
- 52 Week High
- AXIL $10.75
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- AXIL 77.65
- INKT 49.44
- Support Level
- AXIL $6.50
- INKT $18.54
- Resistance Level
- AXIL $8.85
- INKT $20.25
- Average True Range (ATR)
- AXIL 0.75
- INKT 8.24
- MACD
- AXIL 0.29
- INKT -1.13
- Stochastic Oscillator
- AXIL 86.74
- INKT 13.41
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.